Royalty Pharma (Nasdaq:RPRX) - Stock Price, News & Analysis

RPRX Stock Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.

RPRX fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	0/6
Financial Health	3/6
Dividends	1/6

Rewards

Trading at 77.6% below our estimate of its fair value

Earnings are forecast to grow 82.67% per year

Analysts in good agreement that stock price will rise by 87%

Risk Analysis

Dividend of 3.01% is not well covered by earnings or cash flows

Significant insider selling over the past 3 months

Has a high level of debt

Large one-off items impacting financial results

+ 1 more risk

Royalty Pharma plc Competitors

Viatris

NasdaqGS:VTRS

US$11.7b

Organon

NYSE:OGN

US$4.6b

Corcept Therapeutics

NasdaqCM:CORT

US$3.3b

Zoetis

NYSE:ZTS

US$81.8b

Price History & Performance

Summary of all time highs, changes and price drops for Royalty Pharma
Historical stock prices
Current Share Price	US$26.61
52 Week High	US$44.47
52 Week Low	US$25.92
Beta	0.40
1 Month Change	-11.92%
3 Month Change	-10.82%
1 Year Change	-33.27%
3 Year Change	-35.43%
5 Year Change	n/a
Change since IPO	-40.20%

Recent updates

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25

Royalty Pharma Offers A Unique Long-Term Investment Opportunity

Mar 01

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Jan 25

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Jan 11

Royalty Pharma: A Pharma-Like Company Without The Same Risks

Dec 27

Royalty Pharma Provides Unique Diversity To A Biopharma Portfolio

Oct 27

Royalty Pharma (RPRX) MorphoSys Transaction Call

Jun 11

Royalty Pharma: A Potentially Long-Term Dividend Investment

May 04

Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% Dividend

Mar 08

Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?

Feb 01

Royalty Pharma raises dividend by 13% to $0.17 per share

Jan 08

Shareholder Returns

	RPRX	US Pharmaceuticals	US Market
7D	-4.9%	-2.0%	-2.7%
1Y	-33.3%	11.9%	16.8%

Return vs Industry: RPRX underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.

Return vs Market: RPRX underperformed the US Market which returned 15.1% over the past year.

Price Volatility

Is RPRX's price volatile compared to industry and market?
RPRX volatility
RPRX Average Weekly Movement	2.8%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	5.5%
10% most volatile stocks in US Market	14.2%
10% least volatile stocks in US Market	2.5%

Stable Share Price: RPRX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: RPRX's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1996	n/a	Pablo Legorreta	https://www.royaltypharma.com

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Royalty Pharma plc Fundamentals Summary

How do Royalty Pharma's earnings and revenue compare to its market cap?
RPRX fundamental statistics
Market Cap	US$15.97b
Earnings (TTM)	US$254.95m
Revenue (TTM)	US$2.36b

46.9x

P/E Ratio

5.1x

P/S Ratio

Is RPRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
RPRX income statement (TTM)
Revenue	US$2.36b
Cost of Revenue	US$973.94m
Gross Profit	US$1.39b
Other Expenses	US$1.13b
Earnings	US$254.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.57
Gross Margin	58.76%
Net Profit Margin	10.80%
Debt/Equity Ratio	72.6%

How did RPRX perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

136%

Payout Ratio

RPRX Stock Overview

Rewards

Risk Analysis

Royalty Pharma plc Competitors

NasdaqGS:VTRS

US$11.7b

NYSE:OGN

US$4.6b

NasdaqCM:CORT

US$3.3b

NYSE:ZTS

US$81.8b

Price History & Performance

Recent News & Updates

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Recent updates

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock

Insider notifies of intention to sell stock

Director notifies of intention to sell stock

Founder recently bought US$7.7m worth of stock

Consensus EPS estimates increase by 243%

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of US$0.20 per share at 2.4% yield

First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)

Consensus EPS estimates increase by 46%

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Director recently sold US$5.1m worth of stock

Insider recently sold US$932k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.20 per share at 2.1% yield

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023

Consensus forecasts updated

Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023

Royalty Pharma Announces Expansion of Senior Leadership Team

Director recently sold US$2.5m worth of stock

Director recently sold US$16m worth of stock

Director notifies of intention to sell stock

Director recently sold US$5.1m worth of stock

Consensus forecasts updated

High number of new and inexperienced directors

Upcoming dividend of US$0.19 per share

Royalty Pharma Declares Fourth Quarter 2022 Dividend, Payable on December 15, 2022

Royalty Pharma plc Announces Executive Changes

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Royalty Pharma plc to Report Q3, 2022 Results on Nov 08, 2022

Director recently sold US$43m worth of stock

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Director recently sold US$2.0m worth of stock

Upcoming dividend of US$0.19 per share

Second quarter 2022 earnings: EPS misses analyst expectations

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 85% stake in Theravance Respiratory Company, LLC.

Royalty Pharma plc Declares Third Quarter 2022 Dividend, to Be Paid on September 15, 2022

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

Royalty Pharma declares $0.19 dividend

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

Royalty Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Director recently sold US$1.3m worth of stock

Royalty Pharma plc Announces Directorate Change

Insider recently sold US$4.2m worth of stock

Insider recently sold US$4.0m worth of stock

Royalty Pharma: Unique Diversification, Bear Market Performer

Director recently sold US$5.9m worth of stock

Upcoming dividend of US$0.19 per share